Haematologica Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED 2021
• PROSPECTIVE STUDY OF THE IMMUNOLOGICAL RES PONSE TO FACTOR VIII IN SEVERE HEMOPHILIA A PATIENTS DURING IMMUNE TOLERANCE INDUCTION TREATMENT 2019
• RFVIIIFC FOR FIRST-TIME IMMUNE TOLERANCE INDUCTION (ITI) THERAPY: INTERIM RESULTS FROM THE GLOBAL, PROSPECTIVE VERITI-8 STUDY 2019
• MIR-22 SERUM A NEW NON INVASIVE PROGNOSTIC MARKER IN PATIENTS AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY 2018
• LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-IVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA. PRELIMINARY RESULTS OF A PROSPECTIVE STUDY 2017
• DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY 2017
• LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA 2017
• CONSTRUCTION OF A DECISION MODEL TO AID TREATMENT CHOICES FOR EARLY STAGE HODGKIN LYMPHOMA: BRINGING SURVIVORSHIP FORWARD 2016
• A PHASE 1B/2 STUDY OF SELINEXOR IN COMBINATION WITH BACKCONE THERAPIES FOR TREATMENT OF RELAPSED/REFACTORY MULTIPLE MYELOMA 2016
• ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL) 2015
• OPTIMAL DURATION OF ANTICOAGULANT THERAPY FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS 2015
• ANTI-TUMOR ACTIVITY OF SELINEXOR (KPT-330), AN ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), +/- DEXAMETHASONE IN MULTIPLE MYELOMA PRECLINICAL MODELS & TRANSLATION IN PATIENTS WITH MULTIPLE MYELOMA 2014
• EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR 2014
• THE IMPACT OF BLEEDING COMPLICATIONS IN PATIENTS RECEIVING NOVEL ORAL ANTICOAGULANTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2014
• THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS ( ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY 2013
• END OF TREATMENT BUT NOT INTERIM PET SCAN PREDICTS OUTCOME IN NON-BULKY LIMITED STAGE HODGKIN LYMPHOMA 2010
• IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY' 2010
• PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS 2010
• A CONDITIONAL KNOCK-IN ALLELE OF THE TYPE A CYTOPLASMIC NUCLEOPHOSMIN MUTATION COOPERATES WITH A NOVEL SLEEPING BEAUTY TRANSPOSON TO CAUSE ACUTE MYELOID LEUKAEMIA IN MICE 2010
• IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY' 2010
• PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS 2010
• PROFILING OF MICRORNA EXPRESSION IN PURIFIED HEMATOPOIETIC POPULATIONS AND IN SINGLE CELLS 2010
• COMPARATIVE ANALYSIS OF SHWACHMAN-DIAMOND SYNDROME TO OTHER INHERITED MARROW FAILURE SYNDROMES 2009
• GENETIC ANALYSIS OF INHERITED BONE MARROW FAILURE SYNDROMES FROM ONE COMPREHENSIVE COHORT OF PATIENTS 2009
• MALIGNANT MYELOID TRANSFORMATION IN INHERITED BONE MARROW FAILURE SYNDROMES 2009
• THE IMPACT OF DEEP VEIN THROMBOSISON ON OUTCOMES IN CRITICALLY ILL PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2008
• THE IMPACT OF DEEP VEIN THROMBOSISON ON OUTCOMES IN CRITICALLY ILL PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2008
• EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS 2008
• EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS 2008
• PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION WITH TAPERED DOSE WARFARIN 2008
• PHARMACOKINETICS (PK) OF SUBCUTANEOUS FONDAPARINUX 1.5 MG IN PATIENTS WITH MODERATE RENAL IMPAIREMENT (MRI) 2008
• Pharmacokinetics of the reformulated B-DOMAIN deleted recombinant factor VIII (BDD-RFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS) 2007
• High interleukin-15 expression levels in initial diagnostic leukemic cells of children with acute lymphoblastic leukemia are associated with subsequent relapse involving the central nervous system 2007
• Outcomes ofthrombolysis for repeated courses of systemic tissue plasminogen activator for intravascular thrombosis in children 2007
• Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenicand one-stage assays with pooled normal plasma and refacto laboratory standard 2007
• The preliminary report for the early prediction of therapeutic response in multiple myeloma patients by interim 18F-FDG-PET/CT 2007
• Overview of the clinical results of pentasaccharide in major orthopedic surgery 2001
• Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study. 2024
• Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study.  108:3384-3391. 2023
• High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes.  108:532-542. 2023
• Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy.  107:1219-1221. 2022
• Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study.  106:1991-1994. 2021
• Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity..  105:2391-2399. 2020
• Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity.  105:2391-2399. 2019
• Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.  104:e474-e477. 2019
• T-cell large granular lymphocytic leukemia and plasma cell disorders.  104:e108-e110. 2019
• Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.  104:e51-e53. 2019
• Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells.  104:82-92. 2019
• Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.  103:e505-e509. 2018
• GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.  103:e395-e399. 2018
• Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.  103:1229-1234. 2018
• Iron overload in transfusion-dependent survivors of hemoglobin Bart’s hydrops fetalis.  103:e184-e187. 2018
• CD56 ^bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.  102:1936-1946. 2017
• Hb S/ +-thalassemia due to Hb sickle and a novel deletion of DNase I hypersensitive sites HS3 and HS4 of the   locus control region.  100:e166-e168. 2015
• The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.  100:633-642. 2015
• Thrombosis is associated with inferior survival in multiple myeloma.  97:1603-1607. 2012
• Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded.  97:1507-1513. 2012
• Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors.  95:1952-1959. 2010
• Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review.  94:850-856. 2009
• Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.  93:1728-1733. 2008
• Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V.  93:1273-1275. 2008
• Inflammation and oxidant-stress in  -thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.  93:817-825. 2008
• SBDS-deficient cells undergo accelerated apoptosis through the Fas-pathway.  93:363-371. 2008
• Acute pancreatitis preceding thrombotic thrombocytopenic Purpura.  92:e94-e95. 2007
• Hb Evora [ 2 35, Ser->Pro], a novel hemoglobin variant associated with an  -thalassemia phenotype.  92:e68-e68. 2007
• The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia.  91:1530-1537. 2006
• The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia..  91:1530-1537. 2006
• High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C..  91:1367-1371. 2006
• Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.  91:976-979. 2006
• Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study..  91:976-979. 2006
• Determining the cause of patchwork HBA1 and HBA2 genes: recurrent gene conversion or crossing over fixation events.  91:297-302. 2006
• Determining the cause of patchwork HBA1 and HBA2 genes: recurrent gene conversion or crossing over fixation events..  91:297-302. 2006
• Home-treatment of deep vein thrombosis in patients with cancer..  90:150. 2005
• Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo..  90:166-172. 2005
• Oral vitamin K produces a normal INR within 24 hours of its administration in most patients discontinuing warfarin..  90:137-139. 2005
• Thromboprophylaxis practice patterns in two Western Australian teaching hospitals..  89:586-593. 2004
• SDF-1 enhances the expansion and maintenance of highly purified human hematopoietic progenitors.  4:137-145. 2003
• Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia..  87:948-956. 2002
• Selecting patients for home treatment of deep vein thrombosis: the problem of cancer..  87:286-291. 2002
• Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism.  3:311-314. 2002
• Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success..  86:1186-1193. 2001
• Overview of the clinical results of pentasaccharide in major orthopedic surgery..  86:59-62. 2001
• IgG subclasses on the lymphocyte surface in chronic lymphocytic leukemia (CLL)..  70:75-77. 1985

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• Immunology (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0390-6078
• 1466-4860

Electronic International Standard Serial Number (EISSN)

• 1476-5632
• 1592-8721